Updating the paradigm: inflammation as a targetable modulator of medial vascular calcification
Cardiovascular Research · 24.10.2023 · 119 (13) · 2259-2261
DOI: 10.1093/cvr/cvad139 ↗Kurz gefasst
Editorial in der Zeitschrift Cardiovascular Research, online erschienen am 24.10.2023. Verfasst von Mandy E Turner und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular Medicine, Department of Medicine, Center for Interdisciplinary Cardiovascular Sciences, Brigham and Women's Hospital, Harv…. Hauptthemen laut MEDLINE: Vascular Calcification. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
This editorial refers to ‘Sodium-glucose cotransporter 2 inhibitor canagliflozin alleviates vascular calcification through suppression of nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 inflammasome', by A. Chen et al., https://doi.org/10.1093/cvr/cvad119. Arterial calcification is a strong independent predictor of cardiovascular morbidity and mortality.1,2 For many years, much effort has been placed into unravelling the mechanistic underpinnings of pathological vascular calcification: however, our treatment approaches have not similarly advanced and therapies that directly target this pathology are still an unmet clinical need. Vascular calcification can be broadly classified into two types by its location within the vessel wall (Figure 1). In the intimal layer, calcification typically associates with atherosclerotic plaques. In early stages, small (5–15 µm) spotty microcalcifications, which are below the limit of detection of traditional imaging modalities, likely destabilize the plaque, thus increasing the risk of rupture and subsequent thrombotic events.3 High local inflammation, immune cell infiltration, and pro-inflammatory lipid deposition in plaques contribute to calcification inception. The therapeutic implications of these benchtop findings are only recently coming to clinical fruition with randomized controlled trials showing reductions of atherosclerotic cardiovascular morbidity through modulation of inflammation.4 Distinguishing features of the inflammatory profile in intimal and medial vascular calcification. Intimal vascular calcification, concomitant with atherosclerosis, is hallmarked by risk factors such as hyperlipidemia, hypertension, and diabetes. Local immune cell infiltration and pro-inflammatory lipid deposition in the tunica intima precipitates calcification. Medial calcification is hallmarked by chronic kidney disease, advancing age, and diabetes as well, however it is not typically coupled strongly with local inflammation. This article updates the current paradigm by showing that attenuating local smooth muscle cell inflammatory pathways (NLRP3 and IL1-β) through SGLT2 inhibitor canaglifozin can reduce calcification in the tunica media. In contrast, medial calcification may occur simultaneously throughout the vascular tree as circumferential sheet-like deposits of hydroxyapatite. It is most often considered in the context of impaired mineral homeostasis in chronic kidney disease but also occurs with healthy ageing and in diabetic patients. These calcific deposits decrease vascular compliance, causing local tissue stress, and increase afterload on the heart. In both intimal and medial vascular calcification, resident smooth muscle cells (SMCs) acquire an osteoblastic-like phenotype capable of secreting extracellular vesicles that facilitate the deposition of hydroxyapatite into the collagenous extracellular matrix.5 Medial vascular calcification is not typically conceptualized as a local inflammatory process; however, recent findings suggest this paradigm may need to be expanded and that local inflammation may be a targetable pathway in this disease. Sodium–glucose cotransporter-2 (SGLT2) inhibitors improve glycaemic control in patients with Type 2 diabetes through blockage of glucose reabsorption in the kidney. Clinical trials have linked these drugs to reductions in cardiovascular events and heart failure in both diabetic and non-diabetic patients. These phenomena are unexplainable by improvements in glycaemic control alone and are, at least in part, due to pleiotropic effects.6 There have been reports of SGLT2 inhibitors affecting vascular outcomes, such as reduced markers of vascular stiffness; however, a mechanism has yet to be elucidated.7,8 Yan and colleagues9 present evidence that clinically relevant doses of SGLT2 inhibitor canagliflozin can prevent medial calcification through the direct and local attenuation of SMC inflammatory pathways. Utilizing normoglycaemic animal models of medial vascular calcification, in vitro SMC culture, and ex vivo vessel culture, they convincingly showed a direct effect of canagliflozin on vasculature through modulation of the NLRP3 inflammasome. In SMC culture, canagliflozin also attenuated increases in IL1-β. IL-1β is the main product of NLRP3 activation associated predominantly with macrophages, a cell which SGLT2 inhibitors are known to modulate. IL-1β is the target of the monoclonal antibody therapy canakinumab, which has been shown to reduce the rate of atherosclerotic cardiovascular events.10 In this study by Yan and colleagues, upstream inhibition or silencing of NLRP3 attenuated in vitro SMC calcification and mitigated molecular signatures of osteoblastic transdifferentiation. Conceptualizing medial calcification as, at least in part, a pathology driven by local inflammatory pathways in SMC presents a paradigm for future drug exploration and potential drug repurposing. Unresolved by this study is the mechanism by which SGLT2 inhibitors, or canagliflozin specifically, are able to attenuate NLRP3 activation and thus its downstream inflammation. The questions whether it enacts this response through SGLT2 receptor or through another novel pleiotropic and thus targetable mechanism or whether it has any potential role in calcification reversal in addition to prevention remain. It should be noted that the calcific stimuli used in this study are hypercalcaemic in nature. The mouse and rat models were both supplemented with vitamin D analogues, and the osteogenic media was calcium-supplemented. While it is not definitive that calcium is the primary driver of vascular calcification in these models, it likely contributes and is not typically present in the clinical milieu of medial vascular calcification. These findings should be further explored in normocalcaemic models of medial vascular calcification. Further, medial vascular calcification is a phenomenon that occurs over decades in humans, rather than days or weeks. While these in vitro and in vivo models are the current scientific standard, they always present with human generalizability limitations. While data strongly suggest vascular calcification confers substantial cardiovascular risk, due to a lack of therapeutics that directly modulate vascular calcification in humans, the magnitude of risk reduction that would be achieved by preventing or reversing vascular calcification has yet to be definitively established. Expedited drug target discovery is a rapidly evolving process using unbiased discovery-based methods, with already available compounds and drugs aiding in machine learning-driven novel drug development. In addition, pleiotropic effects of currently available pharmaceuticals, with already available safety profiles, are an excellent resource for expedited treatment options. Of specific relevance in cardiovascular calcification is the need to prevent off-target effects on the bone. Some mechanisms of ectopic vascular calcification and bone mineralization are shared, and demineralization or prevention of mineralization in the vasculature may negatively modulate bone metabolism in an ageing population already at high risk for osteoporosis. Mouse models and clinical trials (EMPA-REG, DECLARE, CANVAS-RCT) are conflicting on whether there is an effect of SGLT2 inhibitors on bone metabolism, with at least some suggesting a negative overall impact.11 Whether these potential impacts on bone are related to the mechanism Yan and colleagues observed in the vasculature is unclear. Advancements in our understanding of the pathobiology of vascular calcification will, with hope, be fruitful in aiding drug discovery. Recent discoveries support that local inflammatory pathways in SMCs that are responsive to calcific stimuli are a potential axis for intervention in medial calcification. There is substantial interest in developing drugs that directly modulate vascular calcification and pleiotropic effects of currently available pharmaceuticals are a rich source for expedited mechanistic drug discovery and clinical utility. Elena Aikawa lab is supported by National Institutes of Health (NIH) grants: R01HL147095, R01HL141917, and R01HL136431.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Division of Cardiovascular Medicine, Department of Medicine, Center for Interdisciplinary Cardiovascular Sciences, Brigham and Women's Hospital, Harvard Medical School, 3 Blackfan St, Boston, MA 02115, USA.
- Division of Cardiovascular Medicine, Department of Medicine, Center for Excellence in Vascular Biology, Brigham and Women's Hospital, Harvard Medical School, 77 Louis Pasteur Ave, Boston, MA 02115, USA.
ORCID-Profile: Elena Aikawa
Förderung
- NHLBI NIH HHS
- National Institutes of Health
Zitieren
APA
Turner, M. E., & Aikawa, E. (2023). Updating the paradigm: inflammation as a targetable modulator of medial vascular calcification. Cardiovascular Research, 119(13), 2259-2261. https://doi.org/10.1093/cvr/cvad139
Vancouver
Turner ME, Aikawa E. Updating the paradigm: inflammation as a targetable modulator of medial vascular calcification. Cardiovascular Research. 2023;119(13):2259-2261. doi:10.1093/cvr/cvad139
BibTeX
@article{Turner2023,
author = {Turner, Mandy E and Aikawa, Elena},
title = {Updating the paradigm: inflammation as a targetable modulator of medial vascular calcification},
journal = {Cardiovascular Research},
year = {2023},
volume = {119},
number = {13},
pages = {2259--2261},
doi = {10.1093/cvr/cvad139}
}
EUVIMED